drug
VAX-31
Phase 3updated 6mo agoby $PCVX Vaxcyte, Inc.
Phase 3community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying VAX-31
News(9)
- Pfizer flat in Q3 despite 32% growth for new and acquired productsSales of assets from Seagen and Biohaven grew in the third quarter, but it wasn’t enough for Pfizer to overcome declines across the Prevnar and COVID franchises.biospace · 15d ago
- Vaxcyte's pneumococcal vaccine succeeds in Phase 3, stock surgesVaxcyte's shares {$PCVX} jumped 35% Monday morning after the company announced that its experimental pneumococcal vaccine VAX-31 met its key endpoints in a Phase 3 trial with adults, a major step i…endpoints · 1mo ago
- Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine dataThe company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer and Merck on nearly all bacterial strains in the first of three Phase 3…biopharma_dive · 1mo ago
- Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, MerckVAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ambitious scenario and setting Vaxcyte up to challenge the Big Pharmas in a…biospace · 1mo ago
- STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and moreVaxcyte said its pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up a competition with Pfizer and Merckstat · 1mo ago
- STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine marketVaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.stat · 1mo ago
- Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shotsVaxcyte has seen its stock jump after the biotech’s 31-valent pneumococcal vaccine candidate went head-to-head with Pfizer’s Prevnar 20 and Merck & Co.’s Capvaxive in a phase 3 contest.fiercebiotech · 1mo ago
- Chutes & Ladders—Longtime Takeda R&D chief to depart next JuneTakeda President of Research and Development Andy Plump, M.D., Ph.D., is leaving the company in June after twelve years in the position.fiercebiotech · 2mo ago
- 10 clinical trials to watch in the second half of 2026The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.biopharma_dive · 4mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that